

Medartis shareholders approve all proposals at the AGM 2024

- 82.1% of the total share capital was represented at this year's Annual General Meeting
- All proposals by the Board of Directors were approved with a large majority
- The new sustainability report was approved with 99.9% of the votes
- Martha Shadan and Jennifer Dean were elected as new members to the Board while Dr. med. Daniel B. Herren did not stand for re-election

Basel, 17 April 2024: The shareholders of Medartis Holding AG (SIX: MED) today approved all the substantive proposals of the Board of Directors with a clear majority of more than 94.8%. All members of the Board of Directors standing for election were elected with more than 91.5% of the votes represented. As in the previous year, the General Assembly took place physically at the Medartis headquarters in Basel.

A total of 11,136'019 shares were directly or indirectly represented at the Annual General Meeting, representing 82.1% of the total share capital. The shareholders granted discharge to the members of the Board of Directors (BOD) for their activities during the term of office from the Annual General Meeting 2023 until the Annual General Meeting 2024. In three separate votes, the shareholders approved the maximum total remuneration of the Board of Directors from the AGM 2024 to the AGM 2025 and the maximum total fixed and variable remuneration of the Executive Management Board. The Annual General Meeting also approved the company's 2023 financial report with 100% and approved the remuneration report in a consultative vote with 94.8% of all shares represented.

Vote on the report on non-financial matters

With the introduction of new provisions regarding transparency on non-financial matters in the Swiss Code of Obligations, Medartis was, for the first time, obliged to prepare a report on non-financial matters (also referred to as ESG report) for the 2023 financial year and to submit it to the shareholders. The shareholders approved the report with 99.9%.

In addition to chairman Marco Gadola, all members of the Board of Directors with exception of Dr. med. Daniel B. Herren were re-elected for a one-year term of office until the AGM 2025. After seven years serving on the Board of Directors at Medartis, Dr. med. Daniel B. Herren decided not to stand for re-election at the Annual General Meeting 2024. The Board of Directors proposed Martha Shadan and Jennifer Dean as new members and both were appointed as independent non-executive directors with shareholder approval.

Marco Gadola was elected by the Annual General Meeting as a new member of the Human Resources and Compensation Committee (HRCC) and now serves on this committee together with Damien Tappy.

As of today's Annual General Meeting, the Medartis Board of Directors consists of the following members:

NAME	POSITION	COMMITTEE MEMBERSHIP	FIRST ELECTED	END CURRENT PERIOD
Marco Gadola	Chairman	Member HRCC	2021	2025
Dr. h.c. Thomas Straumann	Vice Chairman	Member SIC	1998	2025
Willi Miesch	Member of the Board	Chair SIC	2010	2025
Damien Tappy	Member of the Board	Chair HRCC	2018	2025
Nadia Tarolli Schmidt	Member of the Board	Chair FAC	2022	2025
Ciro Roemer	Member of the Board	Chair UEC	2022	2025
Martha Shadan	Member of the Board	Member UEC	2024	2025
Jennifer Dean	Member of the Board	Member FAC	2024	2025

HRCC = Human Resources and Compensation Committee | SIC = Strategy and Innovation Committee

FAC = Finance and Audit Committee | UEC = US Expansion Committee

In accordance with the proposal of the Board of Directors, the shareholders confirmed the re-election of Neovius AG as independent voting representative and Ernst & Young AG as statutory auditors.

For a detailed listing of all resolutions at the 2024 Annual General Meeting, please visit [this link](#). The next Annual General Meeting is scheduled to take place on 25 April 2025. Medartis will report its first-half year results 2024 on 20 August 2024.

About Medartis

Founded in 1997 and headquartered in Basel, Switzerland, Medartis is one of the world's leading manufacturers and providers of medical devices for surgical fixation of bone fractures for upper and lower extremities as well as for the craniomaxillofacial region. Medartis employs approx. 830 individuals across its 13 locations, with products offered in over 50 countries globally. Medartis is committed to providing surgeons and operating theatre personnel with the most innovative titanium implants and instruments as well as best-in-class service. For more information, please visit www.medartis.com.

Your contact:

Corporate Communications

Investor contact: investor.relations@medartis.com

Media contact: corporate.communication@medartis.com

Phone +41 61 633 37 36

Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Medartis Holding AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions. Further, neither the company nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained herein or of the views given or implied.